Genetic testing is an increasingly important part of the clinical pathway for Motor Neurone Disease (MND), but it is not a standard requirement for every diagnosis. In the United Kingdom, the decision to undergo genetic testing is typically based on a person’s family history and the specific clinical presentation of their symptoms. While approximately 90 percent of MND cases are sporadic, meaning they occur without a known family link, about 10 percent are familial, where a genetic mutation is passed down through generations. Identifying these mutations can provide clarity for the patient and their family, and in some cases, it may open up opportunities for participation in specialised clinical trials.
Because the results of a genetic test can have significant emotional and practical implications for biological relatives, the process in the UK is managed with great care. It involves specialised genetic counselling to ensure that individuals fully understand the potential outcomes before proceeding. This article explores the difference between the types of MND, the specific genes involved, and the criteria used by UK neurologists to recommend genetic testing.
What we will discuss in this article
- The distinction between sporadic and familial MND
- Common genetic mutations including C9orf72, SOD1, and TARDBP
- The role of the clinical geneticist and genetic counselling
- How genetic testing impacts clinical trial eligibility
- The implications of testing for biological family members
- Emergency guidance for acute neurological changes
Sporadic vs. Familial MND
The primary factor in determining whether genetic testing is appropriate is the family medical history. Clinicians divide MND into two broad categories based on this history.
- Sporadic MND (90%): These cases appear to occur by chance. While there may be some underlying genetic predisposition, there is no clear pattern of inheritance within the family. Genetic testing is less commonly performed in these cases unless the patient is particularly young at onset.
- Familial MND (10%): This is suspected when two or more close relatives, such as a parent, sibling, or child have had MND or a related condition called Frontotemporal Dementia (FTD). In these instances, there is a much higher likelihood of finding a specific causative gene mutation.
Key Genes Associated with MND
Advancements in genomic medicine have identified several specific genes that can cause motor neurone degeneration. In the UK, testing panels usually focus on the most prevalent mutations.
- C9orf72: The most common genetic cause of both MND and FTD. It involves a specific segment of DNA that repeats hundreds or thousands of times.
- SOD1: One of the first genes discovered in relation to MND. Mutations in this gene can lead to a build up of toxic proteins that damage motor neurones.
- TARDBP (TDP 43): This gene provides instructions for a protein that helps regulate other genes. When it malfunctions, it can cause the characteristic protein clumps seen in many forms of MND.
- FUS: Often associated with a younger age of onset, mutations in this gene affect how the cell manages its genetic material.
| Gene Mutation | Frequency in Familial Cases | Association with FTD |
| C9orf72 | ~40% | Very High |
| SOD1 | ~20% | Low |
| TARDBP | ~5% | Moderate |
| FUS | ~5% | Low |
The Testing Process and Genetic Counselling
In the UK, genetic testing for MND is not simply a blood test; it is a comprehensive clinical service. If a neurologist suspects a genetic link, they will refer the patient to a Regional Clinical Genetics Service.
Pre test Counselling
Before any blood is taken, a genetic counsellor will meet with the patient. They discuss why the test is being considered, what a positive or negative result would mean, and how the information might affect their children or siblings. They also address concerns regarding life insurance and psychological well being.
The Decision to Test
The decision to go ahead is entirely voluntary. Some patients choose to test to provide answers for their family or to access gene specific clinical trials. Others prefer not to know, as a positive result can create significant anxiety for relatives who may not want to know their own risk status.
Impact on Treatment and Clinical Trials
One of the most compelling reasons to consider genetic testing is the development of targeted therapies. Researchers are currently investigating treatments that specifically target the SOD1 and C9orf72 mutations. By identifying these mutations early, patients in the UK may be able to join clinical trials for antisense oligonucleotides or other therapies designed to switch off or bypass the faulty gene. While these treatments are not yet standard care, they represent a significant frontier in MND research.
Emergency Guidance
While genetic testing is a forward looking diagnostic tool, certain acute symptoms require immediate medical attention. Seek emergency care immediately if you or someone you care for experience:
- A sudden and severe difficulty with breathing or a feeling of gasping for air
- An acute episode of choking on food or liquid that cannot be cleared
- A total and sudden loss of muscle strength resulting in a fall
- Rapid confusion, disorientation, or a sudden change in mental alertness
In these instances, call 999 or attend the nearest Accident and Emergency department immediately.
To Summarise
Genetic testing is a valuable tool in the management of Motor Neurone Disease, particularly for those with a family history of the condition or Frontotemporal Dementia. While most cases of MND are sporadic, identifying a genetic mutation in familial cases can provide a clearer diagnosis and potentially allow for participation in cutting edge clinical trials. In the UK, the process is supported by specialist genetic counselling to ensure that patients and their families are fully informed of the implications. Ultimately, the choice to undergo testing is a personal one, made in consultation with a multidisciplinary care team to ensure the best possible support for everyone involved.
If I have the C9orf72 gene, will my children definitely get MND?
No. Most familial MND mutations are inherited in an autosomal dominant pattern, meaning each child has a 50 percent chance of inheriting the gene. However, not everyone who inherits the gene will necessarily develop the disease; this is a concept known as reduced penetrance.
Can I get genetic testing if no one else in my family has had MND?
This is typically only considered if you developed symptoms at a very young age (usually under 40) or if you are interested in a specific clinical trial that requires genetic profiling.
How long does it take to get genetic test results?
Because the analysis of these specific genes is complex, it usually takes between two and four months to receive the results through a clinical genetics department.
Will a positive genetic test affect my life insurance?
In the UK, there is a code of practice regarding genetic testing and insurance. Generally, insurers cannot ask for the results of a predictive genetic test for most policies, but they can ask about your family history. You should discuss this with your genetic counsellor.
What is the difference between diagnostic and predictive testing?
Diagnostic testing is done on someone who already has symptoms to find the cause. Predictive testing is done on healthy family members of someone with a known mutation to see if they have inherited the risk.
Are all MND genes known?
No. While we have identified several major genes, research is ongoing to find other genetic factors that may contribute to both familial and sporadic MND.
Is genetic testing available on the NHS?
Yes, genetic testing and counselling for MND are available through the NHS for those who meet the specific clinical criteria, usually involving a strong family history of MND or FTD.
Authority Snapshot
This article was reviewed by Dr. Rebecca Fernandez, a UK-trained physician with an MBBS and extensive experience in internal medicine, general surgery, and emergency care. Dr. Fernandez has managed critically ill patients in intensive care units and stabilized acute trauma cases, providing her with a deep understanding of neurological emergencies and clinical assessment. In her psychiatry work, she has applied evidence based approaches to mood and anxiety disorders, emphasizing the importance of holistic patient care and the integration of digital health solutions. Her expertise ensures that this guide provides a medically accurate and patient centred overview of the role of genetic testing in Motor Neurone Disease.
